Literature DB >> 27912825

Next-Generation Sequencing of Lung Cancers: Lessons Learned and Future Directions.

Siddhartha Devarakonda1, Ashiq Masood2, Ramaswamy Govindan3.   

Abstract

Targeted therapies and immune checkpoint inhibitors have significantly improved outcomes in a sizable fraction of patients with metastatic non-small cell lung cancer. Nevertheless, a majority of patients with lung cancer continue to have poor outcomes. The ability to comprehensively characterize the genomic alterations in various subtypes of lung cancer has the potential to transform cancer care by facilitating the identification of novel treatment strategies. The objective of this review is to summarize key findings from recent studies that have sequenced a large number of lung cancer samples and discuss the diagnostic, prognostic, and therapeutic relevance of these findings. Copyright Â
© 2016 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Lung cancer; Sequencing; Treatment

Mesh:

Substances:

Year:  2017        PMID: 27912825     DOI: 10.1016/j.hoc.2016.08.008

Source DB:  PubMed          Journal:  Hematol Oncol Clin North Am        ISSN: 0889-8588            Impact factor:   3.722


  7 in total

Review 1.  ALK in Non-Small Cell Lung Cancer (NSCLC) Pathobiology, Epidemiology, Detection from Tumor Tissue and Algorithm Diagnosis in a Daily Practice.

Authors:  Paul Hofman
Journal:  Cancers (Basel)       Date:  2017-08-12       Impact factor: 6.639

Review 2.  Immunological-based approaches for cancer therapy.

Authors:  Luciana Barros; Marco Antonio Pretti; Leonardo Chicaybam; Luiza Abdo; Mariana Boroni; Martin Hernán Bonamino
Journal:  Clinics (Sao Paulo)       Date:  2018-08-20       Impact factor: 2.365

Review 3.  A narrative review of prognosis prediction models for non-small cell lung cancer: what kind of predictors should be selected and how to improve models?

Authors:  Yuhang Wang; Xuefeng Lin; Daqiang Sun
Journal:  Ann Transl Med       Date:  2021-10

4.  SLC2A1 plays a significant prognostic role in lung adenocarcinoma and is associated with tumor immunity based on bioinformatics analysis.

Authors:  Yuhang Wang; Hui Wen; Daqiang Sun
Journal:  Ann Transl Med       Date:  2022-05

5.  Establishing a Dedicated Lung Cancer Biobank at the University Center Hospital of Nice (France). Why and How?

Authors:  Kevin Washetine; Simon Heeke; Christelle Bonnetaud; Mehdi Kara-Borni; Marius Ilié; Sandra Lassalle; Catherine Butori; Elodie Long-Mira; Charles Hugo Marquette; Charlotte Cohen; Jérôme Mouroux; Eric Selva; Virginie Tanga; Coraline Bence; Jean-Marc Félix; Loic Gazoppi; Taycir Skhiri; Emmanuelle Gormally; Pascal Boucher; Bruno Clément; Georges Dagher; Véronique Hofman; Paul Hofman
Journal:  Cancers (Basel)       Date:  2018-06-29       Impact factor: 6.639

6.  A Flare for the Unexpected: Bone Flare as Response to Tyrosine Kinase Inhibitor Treatment in a Lung Cancer Patient: New osteoblastic bone lesions in a lung cancer patient may represent bone flare and should not be misdiagnosed as disease progression.

Authors:  Charlotte De Bondt; Annemiek Snoeckx; Jo Raskin
Journal:  J Belg Soc Radiol       Date:  2020-04-27       Impact factor: 1.894

7.  A proteogenomic profile of early lung adenocarcinomas by protein co-expression network and genomic alteration analysis.

Authors:  Toshihide Nishimura; Haruhiko Nakamura; Kien Thiam Tan; De-Wei Zhuo; Kiyonaga Fujii; Hirotaka Koizumi; Saeko Naruki; Masayuki Takagi; Naoki Furuya; Yasufumi Kato; Shu-Jen Chen; Harubumi Kato; Hisashi Saji
Journal:  Sci Rep       Date:  2020-08-12       Impact factor: 4.379

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.